A Phase 1a Study of IMR-687 in Healthy Adult Volunteers
Latest Information Update: 10 Mar 2023
At a glance
- Drugs Tovinontrine (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man
- Sponsors Imara Inc
- 10 Apr 2019 Results published in an Imara Inc Media Release
- 17 Oct 2017 Status changed from recruiting to completed, according to Cydan media release.
- 14 Sep 2017 According to Imara Inc media release, new data will be presented at the 6th Annual Sickle Cell Therapeutics Conference.